Harbour Biomed goes public in Hong Kong

On December 10, BioBAY enterprise Harbour Biomed was officially listed on the Hong Kong Exchanges and Clearing Market (HKEX). It is reported that Harbour Biomed submitted an IPO application to the HKEX in August, and passed the hearing in November. The global offering of 138.22 million shares was listed at an issue price of HK$12.38 per share, and the total amount of funds raised hit HK$1.711 billion. The number of BioBAY-based companies listed on domestic and overseas stock markets has reached 12, including 2 listed on both markets.

BioBAY-based companies listed on domestic and overseas stock markets (By Dec. 10, 2020)


Established in 2016, Harbour Biomed is an innovative biomedical company based in Suzhou that has global operations. It is committed to providing innovative drugs for tumor immunity and immune diseases to patients around the world.  Dr. Wang Jinsong is the founder, chairman and CEO of the company. 


Since its establishment, Harbour Biomed has used two fully human antibody transgenic mouse platforms with global patents to develop breakthrough innovative therapies for tumors and immune diseases. It has worldwide commercial operations in China, the United States and the Netherlands, among others .

Harbour Biomed has built a nearly 3,500 square meter scientific research laboratory in BioBAY, an important cornerstone for its R&D, and introduced Berkley Light's Beacon® single-cell light guide system, making it the first Asia-Pacific company with Beacon single-cell cloning technology. Focusing on the core technology platform, Harbour Biomed has established an innovative drug R&D pipeline through independent research and development, and a diversified cooperation model. Currently, six of its products have entered the clinical research phase with the one under the third phase.

Harbour Biomed’s products


Bartolizumab (HBM9161) is a world-first fully human monoclonal antibody targeting the neonatal crystal fragment receptor (FcRn), which can selectively bind to and inhibit FcRn. As the most cutting-edge FcRn inhibitor in clinical development in Greater China, bartolizumab is expected to provide breakthrough treatments for many autoimmune diseases.

Tenacept (HBM9036) is an innovative TNF receptor 1 fragment for patients suffering moderate to severe xerophthalmia. Through molecular engineering, it can alleviate the symptoms of xerophthalmia. It is specially developed for ophthalmic topical medication. Its tissue distribution, stability and effects are optimized for the treatment of xerophthalmia. In the proof-of-concept and comparability trials carried out in China, Tenacept showed the characteristics of rapid onset, excellent tolerability, and comfort similar to placebo.

In addition, Harbour Biomed has a new generation of fully human anti-CTLA-4 antibody HBM4003, a bispecific antibody HBM9302 targeting HER2 and CD3, and a number of research projects in the early development stage. 

Harbour Biomed has reached an agreement with Utrecht University and Erasmus Medical Center of the Netherlands, and the multinational pharmaceutical company AbbVie to develop a neutralizing antibody 47D11, which can block Covid-19 infections to prevent and treat the pandemic.

In addition, Harbour Biomed also has the industry-leading transgenic mouse platform for antibody drug R&D (Harbour Mice®), the H2L2 platform for generating a new generation of fully human antibodies, and the HCAb platform for generating fully human heavy chain antibodies. The heavy chain antibodies produced by the HCAb platform can not only be independently formulated as medicines, but also be used in the development of bispecific antibodies, multispecific antibodies, CAR-T, and antibody conjugates. Based on the HCAb platform, Harbour Biomed independently developed the HBICE™ immune cell adapter technology platform to produce a new generation of antibody drugs that are expected to achieve therapeutic effects unachievable through combination therapy. Based on HBICE™, Harbour Biomed is also developing HBM7020, HBM7008 and other products.


More than 45 biopharmaceutical and academic institutions across the world have adopted Harbour Biomed's fully human genetically modified antibody platform to develop new antibody drugs, such as Eli Lilly, Pfizer, Cinda, BeiGene and Chia Tai Tianqing.